Treatment of Heart Failure with Sacubitril/Valsartan in Hondurans with reduced left ventricular ejection fraction: Three-year experience.

Francisco Somoza Alvarenga; Rams&eacute;s  Amaya Handal; César Alas-Pineda; Beatriz Mej&iacute;a Raudales; Juan  Toledo Mart&iacute;nez; Isaac Trejo; Francisco Somoza; Ram&oacute;n Mart&iacute;nez Schweinfurth

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Treatment of Heart Failure with Sacubitril/Valsartan in Hondurans with reduced left ventricular ejection fraction: Three-year experience.

Author(s):

Francisco Somoza Alvarenga

¹,

Ramsés Amaya Handal

¹,

César Alas-Pineda

^2,*,

Beatriz Mejía Raudales

³,

Juan Toledo Martínez

³,

Isaac Trejo

³,

Francisco Somoza

⁴,

Ramón Martínez Schweinfurth

⁵

1Clínica Ambulatoria CardioCenter, San Pedro Sula, Cortés, Honduras

2Departamento de Epidemiología, Hospital Dr. Mario Catarino Rivas, San Pedro Sula, Cortés, Honduras

3Universidad Católica de Honduras, Campus San Pedro y San Pablo, San Pedro Sula, Cortés, Honduras

4Internal Medicine, St. Vincent Charity Medical Center, Cleveland, USA

5Hospital CEMESA, San Pedro Sula, Cortés, Honduras

International Cardiovascular Research Journal:Vol. 15, issue 4; e118918

Published online:Dec 31, 2021

Article type:Research Article

Received:Aug 21, 2021

Accepted:Dec 25, 2021

How to Cite:Francisco Somoza Alvarenga, Ramsés Amaya Handal, César Alas-Pineda, Beatriz Mejía Raudales, Juan Toledo Martínez, et al. Treatment of Heart Failure with Sacubitril/Valsartan in Hondurans with reduced left ventricular ejection fraction: Three-year experience..Int Cardiovasc Res J.2021;15(4):e118918.

Abstract

Background: Heart Failure with Reduced Ejection Fraction (HFrEF) is a paramount medical condition affecting more than 23 million individuals worldwide. It is one of the leading causes of morbidity and mortality, particularly in the western world, making it a vital topic of discussion in the current clinical trials.
Objective: This study aimed to describe the response to sacubitril/valsartan in a group of Hondurans with heart failure and reduced Left Ventricular Ejection Fraction (LVEF) between January 2018 and June 2020.
Methods: This observational, descriptive, retrospective cohort study was conducted on 105 adult patients with HFrEF who received treatment with angiotensin-receptor antagonist/neprilysin inhibitors (sacubitril/valsartan) in a single medical center in Honduras. The study participants included the patients with LVEF < 40% treated with sacubitril/valsartan for at least one year. The patients also received optimal medical therapy for HFrEF according to the American Heart Association guidelines. The data were analyzed using the SPSS 25.0 software.
Results: The results showed that the main etiology of HFrEF was ischemic heart disease (41%). The LVEF changed from a median of 30% to 45% after one year of treatment. Additionally, the overall Glomerular Filtration Rate (GFR) remained unchanged. However, the N-Terminal Pro B-type Natriuretic Peptide (NT-ProBNP) decreased from a median of 8800 pg/mL to 1900 pg/mL after 12 months.
Conclusions: The study population had sociodemographic and clinical similarities with the Latin American Cohort in the PARADIGM-HF trial with the significant improvement of the LVEF and functional class. However, the median level of NT-ProBNP was 8800 pg/mL at baseline in the current study, which was dramatically higher than 1760 pg/mL reported in the PARADIGM-HF trial, suggesting the need for further analyses in the Honduran population.

Keywords

Honduras.

Ventricular Ejection Fraction

Heart Failure

Cardiology

Fulltext

The full-text is available in pdf.

References

1.
The references are available in pdf.

comments

Leave a comment here

SAMUEL MEJIA

Jan 31, 2022

Impresionante como este equipo de valiosos investigadores en ciencias medicas nos ponen en alto a nivel internacional no queda mas que felicitar y mas que eso admirarlos de este gran aporte para nuestros conocimiemntos en la practica clinica diaria a los que miramos sindrome metabolico gracias mil saluos

Import into EndNote Import into BibTex

Indexed in

Scopus

Share on

Comments

Number of Comments:1

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Francisco Somoza Alvarenga:[PubMed][Scholar]
Ramsés Amaya Handal:[PubMed][Scholar]
César Alas-Pineda:[PubMed][Scholar]
Beatriz Mejía Raudales:[PubMed][Scholar]
Juan Toledo Martínez:[PubMed][Scholar]
Isaac Trejo:[PubMed][Scholar]
Francisco Somoza:[PubMed][Scholar]
Ramón Martínez Schweinfurth:[PubMed][Scholar]